Abstract
Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide. Radiation therapy (RT) plays an important role in the management of both small cell (SCLC) and non-small cell lung cancer (NSCLC), as 50 to 60% of patients diagnosed with lung cancer will require RT during the course of their disease. In NSCLC, in addition to the use of RT in advanced stage disease, inoperable patients with early-stage disease are now being treated with highly conformal hypofractionated RT as well as radiosurgery. In SCLC, the use of thoracic chemo-RT followed by prophylactic cranial irradiation (PCI) in limited-stage disease, and the use of PCI in extensive-stage disease have improved outcomes, and patient survival has steadily increased in the past decades. This article will review the role of RT in both SCLC and NSCLC, with emphasis at the most recent advances in the field as well as the topics of controversy.
Keywords: Radiation therapy, non-small cell lung cancer, small-cell lung cancer, malignancy, radiosurgery, Inoperable Patients, Stereotactic Radiation Therapy, Chemoradiation, Palliative Radiotherapy, Thoracic Radiation Therapy
Current Respiratory Medicine Reviews
Title: Radiation Therapy in the Management of Lung Cancer
Volume: 7 Issue: 5
Author(s): Tarek Hijal, Jonathan Wan and Luis Souhami
Affiliation:
Keywords: Radiation therapy, non-small cell lung cancer, small-cell lung cancer, malignancy, radiosurgery, Inoperable Patients, Stereotactic Radiation Therapy, Chemoradiation, Palliative Radiotherapy, Thoracic Radiation Therapy
Abstract: Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide. Radiation therapy (RT) plays an important role in the management of both small cell (SCLC) and non-small cell lung cancer (NSCLC), as 50 to 60% of patients diagnosed with lung cancer will require RT during the course of their disease. In NSCLC, in addition to the use of RT in advanced stage disease, inoperable patients with early-stage disease are now being treated with highly conformal hypofractionated RT as well as radiosurgery. In SCLC, the use of thoracic chemo-RT followed by prophylactic cranial irradiation (PCI) in limited-stage disease, and the use of PCI in extensive-stage disease have improved outcomes, and patient survival has steadily increased in the past decades. This article will review the role of RT in both SCLC and NSCLC, with emphasis at the most recent advances in the field as well as the topics of controversy.
Export Options
About this article
Cite this article as:
Hijal Tarek, Wan Jonathan and Souhami Luis, Radiation Therapy in the Management of Lung Cancer, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189704
DOI https://dx.doi.org/10.2174/157339811797189704 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Akt Pathway Inhibitors
Current Topics in Medicinal Chemistry Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Tea and Health: Studies in Humans
Current Pharmaceutical Design Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management
Current Drug Metabolism Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Targeted Cancer Therapeutics: Biosynthetic and Energetic Pathways Characterized by Metabolomics and the Interplay with Key Cancer Regulatory Factors
Current Pharmaceutical Design A New Series of Triazolothiadiazines as Potential Anticancer Agents for Targeted Therapy of Non-Small Cell Lung and Colorectal Cancers: Design, Synthesis, <i>In silico</i> and <i>In vitro</i> Studies Providing Mechanistic Insight into Their Anticancer Potencies
Medicinal Chemistry A Fluorescent g-C3N4 Nanosensor for Detection of Dichromate Ions
Current Analytical Chemistry Pharmacological Modulation of Caspase Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Advances in the Chemistry and Pharmacology of Ecteinascidins, A Promising New Class of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Effects of Extracellular Matrix and Integrin Interactions on Airway Smooth Muscle Phenotype and Function: It Takes Two to Tango!
Current Respiratory Medicine Reviews Modifying Toll-like Receptor 9 Signaling for Therapeutic Use
Mini-Reviews in Medicinal Chemistry Biological Activity Evaluation of Novel 1,2,4-Triazine Derivatives Containing Thiazole/Benzothiazole Rings
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic:Utilizing Chinese Medicines to Improve Cancer Therapy - Fiction or Reality?(Guest Editors: Ying Huang and Moses Sing Sum Chow)]
Current Drug Discovery Technologies Exploration of (hetero)aryl Derived Thienylchalcones for Antiviral and Anticancer Activities
Medicinal Chemistry